On June 18th, 2014, the Indian Patent Office, for the second time, denied a patent to the anti cancer drug Abraxane manufactured by US- Based Abraxis BioSciences. The first rejection by the IPO was earlier in 2009, based on a pre-grant opposition filed by generic drug manufacturer Natco Pharmaceuticals. Earlier this year, SpicyIP had reported that Abraxis had appealed this rejection to the IPAB on the ground of a violation of procedural law (they were not afforded an opportunity to...
↧